Together, these in vivo findings were in agreement with our in vitro results and indicated that Lycorine therapeutically suppressed GBM tumor growth in intracranially orthotopic xenograft model through suppressing the EGFR signaling pathway. This evidence concerns the gene EGFR and glioblastoma.